VA Plans to Expand Psychedelic Access for Veterans
The administration aims to provide these therapies to 2.1 million veterans despite a lack of regulatory safety approval.
Updated on Oct. 25, 2026 in Substance Abuse
Live Poll
Should the government support using unapproved psychedelic drugs to treat veterans with mental illnesses?
In October 2026, the Veterans Health Administration unveiled a plan to expand access to psychedelic drugs for veteran populations. This shift follows an April 2026 executive order by President Donald Trump aimed at accelerating clinical research and patient access for conditions like PTSD and depression.
Why it matters
With millions of veterans facing mental health challenges, the VA is exploring new treatment pathways where traditional options have faced hurdles. This initiative responds to increasing support from Republican lawmakers to address the persistent burden of PTSD and depression among those who have served.
A VA assessment estimates 2.1 million veterans could benefit from psychedelic drugs, a figure representing about one-third of the 6.4 million veterans currently under VA care. To date, no government regulator has deemed psychedelic drugs safe or effective for treating mental illness.
The players
Veterans Health Administration
The agency responsible for providing medical care to approximately 6.4 million veterans across the United States.
President Donald Trump
The current President of the United States who issued an executive order in April 2026 to accelerate psychedelic research.
Food and Drug Administration
The federal agency tasked with evaluating the safety and efficacy of medical treatments and drug therapies.
The details
The Veterans Health Administration is working to expand clinical capacity to facilitate the administration of psychedelic therapies. This follows a 2024 decision by the Food and Drug Administration, which rejected a proposal for MDMA-assisted therapy for PTSD. The current expansion strategy is guided by an executive order from President Donald Trump that mandates faster research and clinical trial development to increase patient access.
Timeline
2024: The FDA rejected MDMA-assisted therapy for PTSD.
April 2026: President Donald Trump issued an executive order on psychedelic research.
October 2026: A VA official addressed a conference regarding increased psychedelic access.
Health Landscape
The VA is prioritizing these treatments despite the 2024 FDA rejection of MDMA-assisted therapy for PTSD. This pivot signals an attempt to reconcile clinical research gaps with the urgent mental health needs of the veteran population.
Veterans or their families interested in how these developments may eventually impact care options should consult with a primary care physician. It is important to remember that no government health agency has approved these substances as safe or effective for clinical treatment.
The takeaway
While research into psychedelics is accelerating under new federal directives, these therapies remain under investigation and lack official regulatory approval for mental illness. Patients should prioritize evidence-based care and discuss any questions about new treatment programs with a qualified physician.
Further reading
For more information on the evolving policies surrounding mental health treatments, visit the Substance Abuse section.
Source note: This article includes information reported by POLITICO.
Live Poll
Should the government support using unapproved psychedelic drugs to treat veterans with mental illnesses?
